AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00400114
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin (65mg/m2)once weekly in weeks 1, 2, 4, 5, 7, and 8
Trial: NCT00400114
Drug: sunitinib (Sutent)
RxNorm normalized name: sunitinib Oral Capsule [Sutent]
DrugBank: Sunitinib (DB01268)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: sunitinib (Sutent), dose range of 12.5mg - 50mg OD x 1 year post op.
Trial: NCT01492712
Drug: Propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients in the low-high-low group will receive an infusion of propofol with an initial blood target concentration of 2 mcg/ml. After 15 minutes the target will be increased to 5 mcg/ml and after a further 15 minutes the target will be reduced back to 2 mcg/ml for a further 15 to 30 minutes.
Trial: NCT01492712
Drug: Propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients in the high-low-high group will receive an infusion of propofol with an initial blood target concentration of 5 mcg/ml. After 15 minutes the target will be reduced to 2 mcg/ml and after a further 15 minutes the target will be increased back to 5 mcg/ml for a further 15 to 30 minutes.
Trial: NCT01619085
Drug: Nintedanib
RxNorm normalized name: Nintedanib
DrugBank: Nintedanib (DB09079)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Nintedanib twice a day
Trial: NCT03935399
Drug: Oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10 IU oxytocin (Pitocin) for intramuscular injection
Trial: NCT03935399
Drug: Saline
RxNorm normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1.5 ml preservative free saline for intramuscular injection
Trial: NCT01686802
Drug: oral morphine
RxNorm normalized name: morphine Oral Tablet
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04661020
Drug: CD19 CAR-T cells
RxNorm normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each subject receive CD19 CAR T-cells by intravenous infusion
Trial: NCT04443751
Drug: SHR-1702
RxNorm normalized name: SHR-A1904
DrugBank: SHR-A1904 (DB18702)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHR-1702 monotherapy, administered IV
Trial: NCT01255787
Drug: Vortioxetine
RxNorm normalized name: Vortioxetine
DrugBank: Vortioxetine (DB09068)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Vortioxetine tablets
Trial: NCT00842894
Drug: insulin detemir
RxNorm normalized name: Insulin Detemir
DrugBank: Insulin detemir (DB01307)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Safety and effectiveness data collection in connection with the use of the drug.
Trial: NCT00842894
Drug: biphasic insulin aspart 30
RxNorm normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Safety and effectiveness data collection in connection with the use of the drug in daily clinical practice.
Trial: NCT01692418
Drug: Ferric carboxymaltose
RxNorm normalized name: Ferric Carboxymaltose
DrugBank: Ferric carboxymaltose (DB08917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1000mg of ferric carboxymaltose will be administered as an i.v. infusion (100ml normal saline)
Trial: NCT03606980
Drug: Dexamethasone Sodium Phosphate
RxNorm normalized name: dexamethasone sodium phosphate
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone sodium phosphate administered via iontophoresis
Trial: NCT03433027
Drug: BB-401
RxNorm normalized name: rPDGF-BB
DrugBank: Becaplermin (DB00102)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: BB-401 1.92ug/mL Intratumoral Injections, every week for up to 8 weeks
Trial: NCT03835728
Drug: Ocrelizumab
RxNorm normalized name: Ocrelizumab
DrugBank: Ocrelizumab (DB11988)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Subjects will be randomized in a 1:1 fashion to receive infusion of Ocrelizumab (2 doses at 300 mg and 1 dose at 600 mg) or matched placebo. The 2 300 mg doses will be administered at day 2 and day 14. The 600 mg dose will be administered during the 6 month visit. The drug will be administered via infusion three times throughout the trial period: after the initial screening, at two weeks from initial infusion, and at 6 months.
Trial: NCT03835728
Drug: Saline
RxNorm normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: This will be the matching placebo used in the study.
Trial: NCT03799874
Drug: Inhaled Carbon Monoxide at 200 ppm
RxNorm normalized name: carbon monoxide
DrugBank: Carbon monoxide (DB11588)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled Carbon Monoxide at 200 ppm for 90 minutes daily for 3 days.
Trial: NCT04331197
Drug: Clomiphene Citrate 50mg
RxNorm normalized name: CLOMIPHENE CITRATE 50MG TAB
DrugBank: Clomifene (DB00882)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clomid 50 mg, 2 tablets orally every day from day 2-5 of the period for 5 days
Trial: NCT04331197
Drug: Letrozole 2.5mg
RxNorm normalized name: LETROZOLE 2.5MG TAB
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Femara 2.5 mg, 2 tablets orally every day from day 2-5 of the period for 5 days
Trial: NCT02951845
Drug: JNJ-54416076 (Oral Suspension)
RxNorm normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive (25 mg) oral suspension of JNJ-54416076 in Part 1 and Part 2.
Trial: NCT02951845
Drug: JNJ-54416076 (Formulation 2: Fluid Bed Granulation Tablets)
RxNorm normalized name: amniotic fluid (bovine)
DrugBank: Human Amniotic Fluid (DB15871)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive JNJ-54416076 Tablet formulation 2 (5\*5 mg Tablets \[25 mg total\]) under fasted and fed condition in Part 2.
Trial: NCT00004328
Drug: enalapril
RxNorm normalized name: Enalapril
DrugBank: Enalapril (DB00584)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00004328
Drug: polystyrene sulfonate
RxNorm normalized name: polystyrene sulfonate
DrugBank: Tolevamer (DB01344)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01772004
Drug: Avelumab
RxNorm normalized name: Avelumab
DrugBank: Avelumab (DB11945)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants received intravenous infusion of Avelumab in dose escalation and expansion cohorts until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.
Trial: NCT00738413
Drug: Deferoxamine
RxNorm normalized name: Deferoxamine
DrugBank: Deferoxamine (DB00746)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Deferoxamine will be administered subcutaneously over 8 hours for 6 days at a dose of 40 mg/kg.
Trial: NCT00738413
Drug: Deferasirox
RxNorm normalized name: Deferasirox
DrugBank: Deferasirox (DB01609)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Deferasirox will be orally administered at a dose of 30 mg/kg once daily for 6 days.
Trial: NCT00184080
Drug: Elsamitrusin
RxNorm normalized name: Elsamitrucin
DrugBank: Elsamitrucin (DB05129)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04744883
Drug: Naloxone
RxNorm normalized name: Naloxone
DrugBank: Naloxone (DB01183)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: In randomized order (crossover) across 2 laboratory sessions each approximately 3 days apart, participants will receive either 1) 2 doses of saline placebo (20ml each) or 2) weight-adjusted doses of Naloxone beginning with a dose of 0.11mg/kg followed by a weight-adjusted dose of 0.055 mg/kg
Trial: NCT01875224
Drug: Belatacept
RxNorm normalized name: Belatacept
DrugBank: Belatacept (DB06681)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT01875224
Drug: Tacrolimus
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard administration of tacrolimus
Trial: NCT03768609
Drug: Pimodivir
RxNorm normalized name: Pimodivir
DrugBank: Pimodivir (DB14974)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will be administered pimodivir 600 mg orally as two tablets of 300 mg each.
Trial: NCT00936091
Drug: vitamin A supplements
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gelatinous and reddish opaque capsules containing 200 000 IU vitamin A
Trial: NCT04388371
Drug: Glutamine
RxNorm normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glutamine will be administered by IV injection prior to PET imaging.
Trial: NCT03768609
Drug: Cyclosporine
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will be administered cyclosporine 400 mg orally as 4 capsules of 100 mg each.
Trial: NCT04499235
Drug: Mometasone furoate
RxNorm normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Topical mometasone furoate
Trial: NCT02176642
Drug: Oxybutynin extended release
RxNorm normalized name: oxyBUTYnin Extended Release Oral Tablet
DrugBank: Oxybutynin (DB01062)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5mg tablet taken by mouth daily for 6 weeks
Trial: NCT01190787
Drug: velcade subcutaneous melphalan prednisone
RxNorm normalized name: Velcade
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: INDUCTION Velcade will be given as subcutaneous (SC) injection. Each cycle will be repeated every 28 days.~Melphalan will be given orally. Each cycle will be repeated every 28 days. Prednisone will be given orally.Each cycle will be repeated every 28 days. MAINTENANCE Velcade will be given a SC injection. Each cycle will be repeated every 28 days.
Trial: NCT01190787
Drug: velcade prednisone
RxNorm normalized name: Velcade
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: INDUCTION Velcade will be given as subcutaneous (SC) injection. Each cycle will be repeated every 28 days.~Prednisone will be given orally.Each cycle will be repeated every 28 days. MAINTENANCE Velcade will be given a SC injection. Each cycle will be repeated every 28 days.
Trial: NCT00419809
Drug: SB-681323 oral tablets
RxNorm normalized name: SB-649868
DrugBank: SB-649868 (DB14822)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01401959
Drug: Eribulin
RxNorm normalized name: Eribulin
DrugBank: Eribulin (DB08871)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 1.4 mg/m\^2 IV Days 1 and 8, every 21 days for six cycles
Trial: NCT01401959
Drug: Trastuzumab
RxNorm normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 6 mg/kg IV Day 1 every 21 days
Trial: NCT03239691
Drug: ACT-709478 for oral use
RxNorm normalized name: ACT-541468
DrugBank: Daridorexant (DB15031)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hard gelatin capsules for oral administration formulated at strengths of 10 mg and 100 mg
Trial: NCT00824070
Drug: Besifloxacin hydrochloride
RxNorm normalized name: BESIFLOXACIN HYDROCHLORIDE
DrugBank: Besifloxacin (DB06771)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Instill besifloxacin study medication in the study eye prior to making an incision for cataract extraction surgery.
Trial: NCT04412876
Drug: Duloxetine
RxNorm normalized name: Duloxetine
DrugBank: Duloxetine (DB00476)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Duloxetine 30 mg qd
Trial: NCT04412876
Drug: Imipramine
RxNorm normalized name: Imipramine
DrugBank: Imipramine (DB00458)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Imipramine 25mg qd
Trial: NCT00824070
Drug: moxifloxacin hydrochloride
RxNorm normalized name: Moxifloxacin Hydrochloride
DrugBank: Moxifloxacin (DB00218)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Instill moxifloxacin study medication in the study eye prior to making an incision for cataract extraction surgery.
Trial: NCT00824070
Drug: gatifloxacin
RxNorm normalized name: Gatifloxacin
DrugBank: Gatifloxacin (DB01044)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Instill gatifloxacin study medication in the study eye prior to making an incision for cataract extraction surgery.
Trial: NCT04268849
Drug: Ferumoxytol
RxNorm normalized name: Ferumoxytol
DrugBank: Ferumoxytol (DB06215)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Ferumoxytol (30 mg/mL) intravenous injection in single use vials.
Trial: NCT04059484
Drug: Amcenestrant
RxNorm normalized name: Amcenestrant
DrugBank: SAR-439459 (DB17864)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: Capsule~Route of administration: Oral
Trial: NCT04059484
Drug: Fulvestrant
RxNorm normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pharmaceutical form: Solution for injection~Route of administration: Intramuscular
Trial: NCT04059484
Drug: Anastrozole
RxNorm normalized name: Anastrozole
DrugBank: Anastrozole (DB01217)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form:Tablets or capsules~Route of administration: Oral
Trial: NCT04059484
Drug: Letrozole
RxNorm normalized name: Letrozole
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: Tablets or capsules~Route of administration: Oral
Trial: NCT04059484
Drug: Exemestane
RxNorm normalized name: Exemestane
DrugBank: Exemestane (DB00990)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: Tablets or capsules~Route of administration: Oral
Trial: NCT04059484
Drug: Tamoxifen
RxNorm normalized name: Tamoxifen
DrugBank: Tamoxifen (DB00675)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: Tablets or capsules~Route of administration: Oral
Trial: NCT01842386
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Subjects will receive intravenous (IV) infusions of rituximab 1 gram on days 1 and 15, and subsequently if indicated up to once a month for 5 months (+/-5 days for each visit) starting approximately on day 42. Subjects whose infections respond positively to the treatment but then relapse may be offered additional treatment.
Trial: NCT00273936
Drug: AVN-944 capsules for oral administration
RxNorm normalized name: lidocaine
DrugBank: AVN-944 (DB05500)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03363464
Drug: Empagliflozin
RxNorm normalized name: Empagliflozin
DrugBank: Empagliflozin (DB09038)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Empagliflozin
Trial: NCT04609865
Drug: Lidocaine 2%
RxNorm normalized name: LIDOCAINE 2% GEL,TOP
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: the lidocaine infusion protocol is a bolus of 1 mg/kg (ideal weight), followed by 3mg/kg/h for the first hour, 1.5 mg/kg/h for the second hour, 0.72 mg/kg/h for the next 22 hours, and then 0.6mg/kg/h for 14 days or until extubation.
Trial: NCT04609865
Drug: Control
RxNorm normalized name: Control
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The NaCl 0,9% infusion protocol is a bolus of 0.05 ml/kg (ideal weight), followed by 0.15 ml/kg/h for the first hour, 0.075 ml/kg/h for the second hour, 0.36 ml/kg/h for the next 22 hours, and then 0.03 ml/kg/h for 14 days or until extubation.
Trial: NCT04268849
Drug: Saline
RxNorm normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Placebo for Ferumoxytol
Trial: NCT00300573
Drug: Dexelvucitabine
RxNorm normalized name: Dexelvucitabine
DrugBank: Dexelvucitabine (DB12470)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nucleoside inhibitor of HIV Reverse Transcriptase
Trial: NCT04268849
Drug: Ferrous sulfate tablets
RxNorm normalized name: Ferrous Sulfate Tablets
DrugBank: Ferrous tartrate (DB13639)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ferrous sulfate tablets containing 60 mg elemental iron
Trial: NCT04268849
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Placebo: Vitamin C, 250 mg, given in the same bottle as the oral iron
Trial: NCT03363464
Drug: DPP-4 inhibitor
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: dipeptidyl peptidase-4 inhibitor
Trial: NCT03451799
Drug: Standard-of-care Temozolomide
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients will receive standard-of-care temozolomide. Temozolomide is not protocol directed.
Trial: NCT02312427
Drug: Starting DPP-4 inhibitor after treatment of heart failure
RxNorm normalized name: BEEF HEART
DrugBank: Beef (DB10509)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After hospitalization, medication for diabetes will be suspended. During the treatment for heart failure, drugs other than DPP-4 inhibitor will be resumed when required. After the stabilization of heart failure, DPP-4 inhibitor will be resumed (or administered if it was not prescribed before hospitalization) and serum BNP before and after the initiation of DPP-4 inhibitor will be measured.
Trial: NCT02312427
Drug: Suspending DPP-4 inhibitor after treatment of heart failure
RxNorm normalized name: BEEF HEART
DrugBank: Beef (DB10509)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After hospitalization, medication for diabetes may be suspended or continued. During the treatment for heart failure, drugs including DPP-4 inhibitor will be resumed when required. After the stabilization of heart failure, DPP-4 inhibitor will be suspended and serum BNP before and after the suspension of DPP-4 inhibitor will be measured.
Trial: NCT04080076
Drug: Oral Tab Tacrolimus
RxNorm normalized name: tacrolimus Extended Release Oral Tablet
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral Tab Tacrolimus (1.0 mg PO BID) in combination with ACTHar 80 Units SQ 2 X week
Trial: NCT00017485
Drug: HPPH
RxNorm normalized name: HPPH
DrugBank: 2-(1-Hexyloxyethyl)-2-devinyl pyropheophorbide-a (DB15243)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04132375
Drug: INM004
RxNorm normalized name: INM004
DrugBank: INM004 (DB17791)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The IMP dose to be studied will be 4 mg of protein/kg of subject's weight. Each vial contains 25 mg protein/mL. Therefore, each subject must receive 0.16 mL/kg.~The IMP will be added to the 100 mL infusion bag of saline solution. Doses will be administered as an infusion at 2.0 mL/min over 50 min with an interval of 24 h between doses.
Trial: NCT00245583
Drug: Topiramate
RxNorm normalized name: Topiramate
DrugBank: Topiramate (DB00273)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: minimum does of 50mg/day
Trial: NCT00665626
Drug: Fostamatinib disodium (R935788)
DrugBank: Tamatinib (DB07159)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R935788 100 mg tablet, orally, twice-a-day
Trial: NCT02949362
Drug: Teduglutide
RxNorm normalized name: Teduglutide
DrugBank: Teduglutide (DB08900)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 0.05mg/kg
Trial: NCT00829283
Drug: Sibutramine/Orlistat
DrugBank: Orlistat (DB01083)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sibutramine 15 mg daily or Orlistat 120mg TID
Trial: NCT04573647
Drug: Cenegermin-Bkbj 0.002% Ophthalmic Solution [OXERVATE]
RxNorm normalized name: Cenegermin-bkbj 0.002% Ophthalmic Solution [OXERVATE]
DrugBank: Cenegermin (DB13926)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Research subjects will use oxervate in affected eye following approved treatment regimen and have their eye measured with optical coherence tomography and a Cochet-Bonnet esthesiometer at various time points before, during and after treatment.
Trial: NCT00667446
Drug: Leuprolide Acetate 3 Month Depot
RxNorm normalized name: leuprolide
DrugBank: Leuprolide (DB00007)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00825851
Drug: Transdermal nicotine patch
RxNorm normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 15mg/16h + 10mg/16h to be used 24h
Trial: NCT00322153
Drug: memantine ER
RxNorm normalized name: memantine Extended Release Oral Capsule
DrugBank: Memantine (DB01043)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 28mg(7mg capsules) once daily and oral administration for 24 weeks.
Trial: NCT02414139
Drug: Capmatinib
RxNorm normalized name: CAPMATINIB
DrugBank: Capmatinib (DB11791)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capmatinib was administered orally, at a dose of 400 mg on a continuous twice daily dosing schedule.~Capmatinib was administered to participants in Cohorts 1a, 1b, 2, 3, 4, 5a and 5b in a fasted state. For Cohorts 6.1. 6.2 and 7, capmatinib was administered either with or without food.
Trial: NCT02133352
Drug: Ranolazine
RxNorm normalized name: Ranolazine
DrugBank: Ranolazine (DB00243)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single arm- ranolazine, initiated at 500 mg BID and increased to 1000 mg BID as tolerated
Trial: NCT03143491
Drug: SOR007 (Uncoated Nanoparticulate Paclitaxel) Ointment
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 1 mL of SOR007 applied topically to the ectocervix once-weekly for four weeks.
Trial: NCT03631355
Drug: Tranexamic Acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: One gram of intravenous tranexamic acid will be administered before tourniquet inflation and 1 gram of IV TXA before closure of the incision.
Trial: NCT04252833
Drug: CT-044
RxNorm normalized name: CT-179
DrugBank: CT-179 (DB17114)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CT-044 HCl is a reactive species decomposition accelerant
Trial: NCT03986697
Drug: Biktarvy
RxNorm normalized name: Biktarvy
DrugBank: Emtricitabine (DB00879)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fixed dose combination preparation containing bictegravir, tenofovir alafenamide and emtricitabine
Trial: NCT03377361
Drug: Trametinib
RxNorm normalized name: Trametinib
DrugBank: Trametinib (DB08911)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Specified dose on specified days
Trial: NCT03377361
Drug: Regorafenib
RxNorm normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Specified dose on specified days